EUDA Company Profile and Key Details

EUDA has shown weak momentum, losing -30.74% over the past week and -49.1% over the past quarter, though year-to-date performance is down -26.84%. Short-term trend indicators are bullishly aligned (SMA20 -10.8%, SMA50 -45.48%, SMA200 -64.01%). The stock’s 14-day RSI is 34.86 (weak momentum), while the ATR of 0.17 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -78.88% below its high and over 27.9% above its low. Average 10-day trading volume of 12.33 thousand shares is below the 3-month average of 23.85 thousand, indicating normal recent market interest.

Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $6.00 to $6.00. The high target offers -15.49% upside. The low target suggests -15.49% downside. The mean target is $6.00. This offers -15.49% upside. EUDA Health Holdings Limited earnings surprise history is a mixed track record. The quarter that ended November 27, 2024, missed forecasts by 0.0%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in October 18, 2024.

EUDA Health Holdings Limited has 37.16 million shares outstanding. The public float is 18.40 million shares, elevated short interest at 0.05% of float. This equals 8.61 thousand shares. The short ratio is 0.09 days. Institutional investors hold 4.59% of the float. Insiders own 50.47%.

EUDA Health Holdings Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$1.44. This means the shares are trading below this model’s fair value.

Our AI price prediction model suggests that EUDA Health Holdings Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -67.89%, with price expected at $2.28 by April 06, 2026, within a range of $0.00 to $4.67 3-Month Outlook: Projected fall of -74.37%, reaching $1.82 by June 19, 2026, with a range of $0.00 to $4.34. 1-Year Outlook: Projected loss of -84.08%, with price at $1.13 by March 23, 2027, within a range of $0.00 to $3.23.

EUDA Health Holdings Limited (NASDAQ:EUDA) shares are down -26.84% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows EUDA Health Holdings Limited trading at a premium to the broader market with a P/E of 65.49. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $6.00, suggesting -15.49% downside. Our AI forecast model points to short-term weakness (-67.89% over two weeks), a medium-term fall (-74.37% over three months), and a longer-term loss (-84.08% over one year), with expected trading ranges indicating moderate volatility.

EUDA Health Holdings Limited (NASDAQ:EUDA) closed at $9.49 USD, gaining $2.39 (33.66%) from the previous close of $7.10. The stock is currently mid-range between its 52-week high and low $6.54 and $86.00. With a market capitalization of about $17.94 million, EUDA Health Holdings Limited is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.12). Key stats such as the average daily volume over the past year has been around 23.19 thousand shares, trading with heavier-than-usual volume. Headquartered in Singapore, None, EUDA Health Holdings Limited operates in the Healthcare sector and the Medical - Healthcare Information Services industry. Led by CEO Alfred Lim, the company employs approximately 117 people and listed since December 14, 2021. EUDA Health Limited develops digital health platform that offers virtual consults for non-emergency medical issues.

EUDA Health Holdings Limited trades at a P/E ratio of 65.49, slightly above the S&P 500 average, with a price-to-sales ratio of 3.44 and a price-to-book ratio of -4.71 indicating negative book value, which may reflect financial stress. The P/FCF stands at -8.42, also below market averages.